ChromaDex appoints Ozan Pamir as CFO effective October 21, 2024; James Lee returns to Controller role

Niagen Bioscience, Inc.

Ozan Pamir named CFO effective Oct 21; succeeds interim CFO James Lee who remains Controller.
Annual base salary of $400,000; target bonus 50% of base; option grant with initial value of $360,000.
Pamir previously CFO of 180 Life Sciences; also held investment banking roles at Ventum Financial.
Option vests: 1/3 one-year anniversary, rest over 24 months; severance: 9 months' base salary on termination without cause.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Ozan Pamir

Chief Financial Officer and Principal Accounting Officer

NAGE · Niagen Bioscience, Inc.

Effective: 2024-10-21
Filed: September 20, 2024, 7:59 PM ET

On September 19, 2024, the Board of Directors (the “Board”) of ChromaDex Corporation (the “Company” or “ChromaDex”) appointed Ozan Pamir as the Company’s Chief Financial Officer and Principal Accounting Officer, effective as of October 21, 2024

Role change

James Lee

Controller

NAGE · Niagen Bioscience, Inc.

Effective: 2024-10-21
Successor: Ozan Pamir
Filed: September 20, 2024, 7:59 PM ET

Mr. Pamir will replace James Lee, who is currently serving as the Company’s Interim Chief Financial Officer and Interim Principal Accounting Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Ozan Pamir was appointed as Chief Financial Officer and Principal Accounting Officer at Niagen Bioscience, Inc..

Action: appointed
Role: Chief Financial Officer and Principal Accounting Officer

Exact text from the filing

On September 19, 2024, the Board of Directors (the “Board”) of ChromaDex Corporation (the “Company” or “ChromaDex”) appointed Ozan Pamir as the Company’s Chief Financial Officer and Principal Accounting Officer, effective as of October 21, 2024

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

James Lee changed role as Controller at Niagen Bioscience, Inc..

Action: replaced
Role: Controller

Exact text from the filing

Mr. Pamir will replace James Lee, who is currently serving as the Company’s Interim Chief Financial Officer and Interim Principal Accounting Officer.

View on SEC.gov

Niagen Bioscience, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-24-040982

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.